Ocugen Inc

Затворен

1.35 1.5

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.34

Максимум

1.37

Ключови измерители

By Trading Economics

Приходи

-5.7M

-25M

Продажби

-45K

1.5M

EPS

-0.07

Марж на печалбата

-1,671.841

Служители

116

EBITDA

-2.5M

-20M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+653.68% upside

Дивиденти

By Acuity

Следващи печалби

4.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

35M

451M

Предишно отваряне

-0.15

Предишно затваряне

1.35

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.09.2026 г., 23:51 ч. UTC

ECB President Lagarde's Upcoming Speech on September 9, 2026, Expected to Address Interest Rates and Inflation Amidst Euro Area Economic Uncertainties.

6.09.2026 г., 23:51 ч. UTC

Correlated Moves

Avalanche is trading higher, boosted by strong performance in correlated assets like Ethereum. It is currently 8.96% above its 20-day moving average.

6.09.2026 г., 23:41 ч. UTC

Investors Brace for September 11 CPI Release Amid Rising Inflation Concerns and Economic Uncertainties

6.09.2026 г., 23:41 ч. UTC

Investors Brace for Key CPI Release on September 11, Anticipating Impact on Inflation Trends and Market Dynamics.

6.09.2026 г., 23:41 ч. UTC

U.S. Inflation Rate Expected to Stabilize at 3.4% Amid Market Caution and Potential Fed Interest Rate Hikes

6.09.2026 г., 23:41 ч. UTC

U.S. Core Inflation Rate Expected at 2.4% Amid Rising Market Volatility and Anticipated Fed Rate Hike Discussions

6.09.2026 г., 23:41 ч. UTC

Core Inflation Rate Expected to Rise 0.2% in August, Sparking Optimism Among Traders Ahead of September Release

6.09.2026 г., 23:41 ч. UTC

U.S. Inflation Rate Expected to Rise by 0.4% in August, Heightening Concerns Over Interest Rate Hikes Amid Strong Job Growth

6.09.2026 г., 23:31 ч. UTC

U.S. Core Producer Prices Expected to Rise 0.3% in August Amid Inflation Concerns and Potential Fed Rate Hikes

6.09.2026 г., 23:21 ч. UTC

U.S. Producer Price Inflation Expected to Rise 0.3% Amid Caution Over Potential Fed Rate Hikes

6.09.2026 г., 23:11 ч. UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid Investor Anticipation of Economic Catalysts

6.09.2026 г., 22:41 ч. UTC

Australia's Westpac Consumer Confidence report set for September 8, 2026, shows cautious optimism amid inflation concerns and rising investor confidence.

6.09.2026 г., 22:31 ч. UTC

Mexican Inflation Rate Expected to Continue Declining Trend Ahead of September 9 Release, Boosting Market Optimism.

6.09.2026 г., 22:31 ч. UTC

Mexico's Inflation Rate Release on September 9, 2026 Expected to Influence Market Dynamics Amid Global Economic Sentiment.

6.09.2026 г., 22:31 ч. UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid mixed market expectations and rising optimism following increased buying activity.

6.09.2026 г., 22:21 ч. UTC

MBA 30-Year Mortgage Rate Release on September 9, 2026, Expected to Show Continued Upward Pressure Amid Inflation and Fed Policy Concerns.

6.09.2026 г., 22:11 ч. UTC

Brazil's Central Bank to Provide Key Insights on Monetary Policy Direction in Upcoming Interest Rate Readout Amid Market Uncertainty

6.09.2026 г., 22:01 ч. UTC

Japan's GDP Growth Forecasted at +1.1% for Q2 2026 Amid Cautious Optimism in Economic Recovery

6.09.2026 г., 22:01 ч. UTC

Japan's GDP Growth Rate Expected at +0.4% Amidst Rising Market Confidence and Global Economic Discussions

6.09.2026 г., 21:51 ч. UTC

Turkey's Central Bank Expected to Maintain 37% Interest Rate Amid Inflation Concerns Ahead of September Decision.

6.09.2026 г., 21:51 ч. UTC

UK Housing Market Faces Continued Pressure as RICS House Price Balance Forecast Improves Slightly to -0.28% Amid Weak Buyer Demand

6.09.2026 г., 21:31 ч. UTC

South Korea's August 2026 unemployment rate release on September 8 sparks cautious optimism amid recent job gains and inflationary pressures.

6.09.2026 г., 21:11 ч. UTC

UK Retail Sales Monitor YoY for August 2026 Expected to Show Modest 1.2% Increase Amid Cautious Consumer Sentiment and Economic Challenges

6.09.2026 г., 21:01 ч. UTC

Spain's Consumer Confidence report on September 8, 2026, shows rising optimism with an index increase to 81.2 amid recovering market sentiment and geopolitical concerns.

6.09.2026 г., 21:01 ч. UTC

Cautious Market Sentiment Ahead of South Africa's Q2 GDP Growth Rate Release Amid Global Economic Fluctuations

6.09.2026 г., 21:01 ч. UTC

South Africa's GDP Growth Rate Release on September 8, 2026 Sparks Market Optimism Amid Global Economic Factors.

6.09.2026 г., 20:21 ч. UTC

Japan's Current Account data set for release on September 7, 2026, forecasts a surplus of JPY 2.87 trillion amid cautious investor sentiment due to historical volatility in outcomes.

6.09.2026 г., 19:01 ч. UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Expected to Reflect Volatile U.S. Inventory Trends Amid Geopolitical Tensions and OPEC+ Production Stability.

6.09.2026 г., 18:51 ч. UTC

Italy's Industrial Production Expected to Rise 0.3% in July Amidst Recent Declines and Economic Concerns

6.09.2026 г., 18:31 ч. UTC

France's Industrial Production Expected to Rise 0.3% in July Amid Economic Uncertainty

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

653.68% нагоре

12-месечна прогноза

Среден 10.25 USD  653.68%

Висок 12 USD

Нисък 8 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat